Staging and response to therapy of malignant pleural mesotheliomaHEELAN, Robert.Lung cancer. 2004, Vol 45, pp S59-S61, issn 0169-5002, SUP1Article

Molecular on/off switchMILTON, Daniel T; RIELY, Gregory J; PAO, William et al.Journal of clinical oncology. 2006, Vol 24, Num 30, pp 4940-4942, issn 0732-183X, 3 p.Article

Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolateKRUG, Lee M; NG, Kenneth K; KRIS, Mark G et al.Clinical cancer research. 2000, Vol 6, Num 9, pp 3493-3498, issn 1078-0432Article

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane^®) given as a two-hour infusionPAIK, Paul K; JAMES, Leonard P; RIZVI, Naiyer A et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 5, pp 1331-1337, issn 0344-5704, 7 p.Article

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor Gefitinib plus carboplatin and paclitaxel in patients with stage IIIb or IV non-small-cell lung cancerMILLER, Vincent A; JOHNSON, David H; KRIS, Mark G et al.Journal of clinical oncology. 2003, Vol 21, Num 11, pp 2094-2100, issn 0732-183X, 7 p.Article

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancerMILTON, Daniel T; RIELY, Gregory J; MILLER, Vincent A et al.Cancer. 2007, Vol 110, Num 3, pp 599-605, issn 0008-543X, 7 p.Article

Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatinLAURIE, Scott A; PFISTER, David G; KRIS, Mark G et al.Clinical cancer research. 2001, Vol 7, Num 3, pp 501-509, issn 1078-0432Article

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancerMILTON, Daniel T; AZZOLI, Christopher G; MILLER, Vincent A et al.Cancer. 2006, Vol 107, Num 5, pp 1034-1041, issn 0008-543X, 8 p.Article

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein : A phase II clinical trialKRUG, Lee M; CRAPANZANO, John P; HEELAN, Robert T et al.Cancer. 2005, Vol 103, Num 10, pp 2128-2131, issn 0008-543X, 4 p.Article

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinomaKRUG, Lee M; MILLER, Vincent A; SHEEHAN, Christine et al.Cancer. 2005, Vol 104, Num 10, pp 2149-2155, issn 0008-543X, 7 p.Article

Overdiagnosis in chest radiographic screening for Lung carcinoma: FrequencyYANKELEVITZ, David F; KOSTIS, William J; HENSCHKE, Claudia I et al.Cancer. 2003, Vol 97, Num 5, pp 1271-1275, issn 0008-543X, 5 p.Article

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to ErlotinibMILLER, Vincent A; RIELY, Gregory J; HERBST, Roy S et al.Journal of clinical oncology. 2008, Vol 26, Num 9, pp 1472-1478, issn 0732-183X, 7 p.Article

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancerMILLER, Vincent A; KRIS, Mark G; TYSON, Leslie et al.Journal of clinical oncology. 2004, Vol 22, Num 6, pp 1103-1109, issn 0732-183X, 7 p.Article

Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR GeneRIZVI, Naiyer A; RUSCH, Valerie; FLORES, Raja et al.Clinical cancer research (Print). 2011, Vol 17, Num 10, pp 3500-3506, issn 1078-0432, 7 p.Article

Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. DiscussionREED, Carolyn E; HARPOLE, David H; SIEGEL, Barry A et al.Journal of thoracic and cardiovascular surgery. 2003, Vol 126, Num 6, pp 1943-1951, issn 0022-5223, 9 p.Conference Paper